Sangamo Therapeutics Inc
SGMO
查看详细走势图
0.400USD
+0.047+13.15%
收盘 02/06, 16:00（美东）报价延迟15分钟
128.80M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+13.15%
5天
-25.30%
1月
-9.93%
6月
-24.51%
今年开始到现在
-4.76%
1年
-68.50%
查看详细走势图
TradingKey Sangamo Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Sangamo Therapeutics Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名161/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价3.81。中期看，股价处于下降通道。近一个月，市场表现较差，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Sangamo Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Sangamo Therapeutics Inc亮点
亮点风险
Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.
业绩增长期
公司处于发展阶段，最新年度总收入57.80M美元
估值合理
公司最新PE估值-0.91，处于3年历史合理位
机构减仓
最新机构持股63.00M股，环比减少43.76%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值808.73K
分析师目标
根据
5
位分析师
买入
评级
3.813
目标均价
+978.50%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Sangamo Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Sangamo Therapeutics Inc简介
Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.
公司代码SGMO
公司Sangamo Therapeutics Inc
CEOMacrae (Alexander D)
网址https://www.sangamo.com/
相关品种
